Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1855838 | 1.00 | ANPEP (0.43) | ANPEPPLAUOPRL1KCNH2CXCR4 | |
| SCHEMBL14012293 | 1.00 | ANPEP (0.43) | ANPEPPLAUOPRL1KCNH2CXCR4 | |
| Hydrochloric Acid SCHEMBL18764693 | 0.98 | ANPEP (0.44) | ANPEPPLAU | |
| Hydrochloric Acid SCHEMBL29505651 | 0.98 | ANPEP (0.44) | ANPEPPLAU | |
| Hydrochloric Acid SCHEMBL31482243 | 0.98 | ANPEP (0.44) | ANPEPPLAU | |
| Hydrochloric Acid SCHEMBL23757874 | 0.98 | ANPEP (0.44) | ANPEPPLAU | |
| Hydrochloric Acid SCHEMBL18765110 | 0.98 | ANPEP (0.44) | ANPEPPLAU | |
| SCHEMBL2084964 | 0.89 | CXCR4 (0.43) | CXCR4 | |
| SCHEMBL2083952 | 0.89 | CXCR4 (0.43) | CXCR4 | |
| SCHEMBL31238644 | 0.89 | CXCR4 (0.43) | CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119707931-A | Intermediate and synthesis method of 1- (1-oxo-1, 2-dihydro-phthalazin-6-yl) cycloalkyl-1-carboxamide derivatives as MTA synergistic inhibitors of PRMT5 | 百济神州(北京)生物科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-118420523-A | Pyridine derivative and application thereof in medicine | 成都百裕制药股份有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-11992494-B2 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-05-28 | — | — | US | disclosed |
| US-20230190763-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11992494-B2 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | PTAFR, PDGFRA, PDGFRB | ANPEP 767/4885PLAU 777/4885OPRL1 382/4885 |
| US-20230190763-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | PTAFR, PDGFRA, PDGFRB | ANPEP 767/4885PLAU 777/4885OPRL1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.